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Abstract
Viral myocarditis is estimated to cause ∼20% of sudden death in people under the age of 40. A
variety of viruses have been found to cause myocarditis including coxsackievirus B3 (CVB3).
Many studies have been performed with CVB3 because there is a mouse model of CVB3-induced
myocarditis. Studies have shown that the TLR3-IFNβ pathway plays a central role in the innate
immune response to CVB3 infection. Our laboratory studies the role of protease activated
receptors (PAR) in different biological responses including viral infection. We examined the effect
of a deficiency in either PAR1 or PAR2 on CVB3-induced myocarditis. Interestingly, we found
that PAR1 knockout mice had increased cardiac injury whereas PAR-2 knockout mice had
decreased cardiac injury. Our studies support the notion that PARs modulate the innate immune
response and can have both positive and negative effects on TLR-dependent responses.
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Viral Myocarditis
Myocarditis can be caused by viral infections of the heart. A variety of viruses have been
proposed to cause myocarditis, including enteroviruses and adenoviruses. Coxsackievirus
B3 (CVB3) is a single-stranded (ss) RNA enterovirus of the Picornaviridae family. It was
one of the first viruses identified to cause myocarditis [1, 2]. Importantly, there is a mouse
model of CVB3-induced myocarditis that can be used to study the innate immune response
to the virus. Myocarditis can be divided into three phases: early, acute and late phases [3]. In
the early phase of infection the virus itself causes cardiac injury by infection of cardiac cells.
In the acute phase, the infection is detected by the innate immune system and immune cells
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are recruited to the heart to kill infected cells and limit viral replication. However, the
immune cells themselves can increase cardiac injury [4]. In the late phase the virus is
eliminated although viral genomes may persist in the heart. Loss of myocardium after
infection leads to remodeling and fibrosis that is associated with impaired heart function and
in severe cases heart failure [2].
Innate immune response in viral myocarditis
Invading pathogens are rapidly detected by the innate immune system. Pathogen-associated
molecular patterns (PAMPs) are detected by pattern recognition receptors (PRRs), such as
Toll-like receptors (TLRs) [5]. Viral infections are mainly detected by the endosomal TLRs
that are activated by nucleic acids, including TLR3, TLR7, TLR8 and TLR9. Double-
stranded (ds) RNA is formed in the cytoplasm during the replication of ssRNA viruses such
as CVB3. Other PRRs involved in the detection of viral infections include the cytoplasmic
receptors melanoma differentiation-associated gene 5 and retinoic acid-inducible gene 1 [6].
The adaptive immune system also plays a major role in host defense against viral infection
[7, 8].
Mouse models of CVB3-induced myocarditis have shown a key role of TLR3 and a
downstream adaptor protein in the innate immune response to infection [9, 10]. Activation
of TLR3 leads to expression of interferons (IFNs) that coordinate the early antiviral response
of the innate immune system [10]. Type I (IFNα and IFNβ) but not type II or III IFNs are
required for an effective early response to CVB3 infection [11, 12]. Cardiac cells express
low levels of IFNα and IFNβ but expression is increased after viral infection. IFNs are also
expressed by immune cells. Type I IFNs expressed by cardiac cells are essential to limit
myocarditis [13]. IFNs induce the expression of IFN-stimulated genes (ISGs) that limit
replication of the virus and recruit immune cells. These ISGs include 2′-5′ oligoadenylate
synthetase/RNase L that limits CVB3 replication and various chemokines, such as CXCL10
[11, 12]. NK cells play an important role in limiting the spread of the infection [14].
Protease-activated receptors
Protease-activated receptors (PARs) are a family of 7 membrane spanning, G-protein
coupled receptors [15]. There are 4 members of the family and they are activated by a
variety of proteases. This allows cells to sense changes in their extracellular environment.
For instance, thrombin generated in the coagulation cascade activates human platelets by
cleavage of PAR1. Interestingly, mouse platelets do not express PAR1 but are activated by
thrombin via a PAR3/PAR4 complex [16]. PAR2 is activated by several proteases, such as
trypsin and tryptase, but not by thrombin [17]. PAR1 and PAR2 are widely expressed in
different cells in the body. Importantly, studies have shown that PAR1 and PAR2 signaling
can be pro-inflammatory and anti-inflammatory depending on the disease model [18]. One
of the challenges in studying PARs in vivo is determining which protease(s) is activating a
given PAR.
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Crosstalk between PARs and TLRs
An early study showed that PARs play a role in the innate immune response to fungal
infection [19]. PAR-dependent signaling was affected by TLR expression/activation and
vice versa [19]. Interestingly, PAR1 and PAR2 had opposite effects. PAR1 promoted
inflammation in response to Candida in a TLR2-dependent manner, whereas PAR-2
attenuated inflammation in response to Aspergillus in a TLR4-dependent manner [19]. The
authors proposed that PARs and TLRs act as a dual-sensor system during infections where
TLRs are activated by PAMPs and PARs are activated by extracellular proteases from the
host and the pathogen [19]. Importantly, another study showed that co-stimulation of PAR2
and TLR4 in a human colonic epithelial cell line led to synergistic induction of the
chemokine IL-8 [20]. Furthermore, PAR2 and TLR4 were found to physically interact after
PAR2 stimulation [20, 21]. A subsequent paper from the Vogel group showed that PAR2
signaling promoted an anti-inflammatory Th2 response in LPS stimulated murine
macrophages [22]. A further study found co-operative signaling between PAR2 and TLR2,
TLR3 and TLR4 for activation of NF-κB and IL-8 expression [23]. However, activation of
PAR2 negatively regulated TLR3-dependent IFNβ expression and ISGs, such as CXCL10
and RANTES, in mucosal epithelial cell lines [23]. Similarly, the Riteau group found that
activation of PAR2 reduced RANTES expression in A549 cells infected with H1N1
influenza A [24]. These data indicated that PAR2 signaling suppresses the TLR3-dependent
antiviral pathway.
Virus Life Cycle
In general, the viral life cycle can be divided into virus entry/infection, virus replication/
assembly and virus release/shedding. CVB3 infection is facilitated by coxsackievirus-
adenovirus receptor and the decay-accelerating factor on the cell surface and subsequent
endocytosis [2]. Changes in virus receptor expression and/or endocytosis may reduce virus
uptake. PARs are internalized by endocytosis and enhance this process after activation [25].
We showed that PAR2 deficiency reduced CVB3 infection and replication in vitro [21].
After virus uptake, the virus has to be unpacked, viral genomes replicated and components
assembled to form new viral particles. This stage is dependent on the cell cycle stage and
p53 expression/activity [26]. IFNβ and ISGs reduce viral replication [11]. We and others
showed that PAR1 enhances and PAR2 decreases IFNβ and ISGs expression after TLR3
stimulation in vitro [21, 23, 27]. We also observed that CVB3 replication in vitro was
reduced in PAR2 deficient cardiac cells due to increased IFNβ expression [21]. In addition,
recent findings have linked p53 to TLR signaling and innate immune responses [28].
Interestingly, PAR1 activation on epithelial cells was shown to increase p53 expression [29]
and p53 is known to inhibit CVB3 replication [26, 30, 31].
The last phase of the viral life cycle is the release of infectious particles. Viral particle
release is often mediated by cell lysis or budding from the membrane. PAR1 activation has
been linked to increased membrane budding which may enhance virus dissemination [32].
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Role of PAR2 in CVB3 infection
Based on in vitro studies showing PAR2 negatively regulated TLR3-dependent IFN-β
expression, it was expected that PAR2 deficient mice would be protected from viral
infections that involved TLR3. We collaborated with Dr. Rauch's group to analyze the effect
of PAR2 deficiency on CVB3 infection. We found that PAR2 deficient mice were protected
from CVB3-induced myocarditis compared to wild-type controls [21]. Infected PAR2
deficient mice had a significantly increased IFNβ mRNA expression and reduced viral load
and inflammation. In vitro studies with murine embryonic cardiac fibroblasts demonstrated
that PAR2 deficient cells expressed higher levels of IFNβ and the chemokine RANTES after
CVB3 infection or stimulation with the dsRNA mimetic polyinosinic acid:polycytidylic acid
(poly I:C) compared with wild-type cells [21]. Furthermore, PAR2 activation inhibited poly
I:C stimulation of Stat-1 phosphorylation, which is activated downstream of the IFN
receptor and is required for expression of ISGs. We conclude that PAR2 signaling
suppresses TLR3-dependent antiviral response to two different ssRNA viruses. At present
we do not know the protease that activates PAR2 in CVB3-induced myocarditis.
Role of PAR1 in CVB3 infection
We determined the effect of PAR1 stimulation on TLR3-dependent IF-β and CXCL10
expression in murine embryonic cardiac fibroblasts. We found that activation of PAR1
increased TLR3-dependent IFNβ and CXCL10 expression in a p38-dependent manner [27].
As expected, PAR-1 deficient cells failed to respond to a PAR1 agonist peptide and
expressed lower levels of IFNβ and CXCL10. These results indicated that PAR1 positively
contributed to the antiviral response of cardiac fibroblasts and predicted that PAR1 deficient
mice would be more susceptible to viral infection compared with wild-type controls. Indeed,
we observed that PAR1 deficient mice expressed lower levels of IFNβ and CXCL10 early
after CVB3 infection and had higher viral genomes and inflammation in the acute phase of
infection. Furthermore, PAR1 deficient mice had increased cardiac injury 8 days after
infection and decreased cardiac function at 28 days after infection compared with wild-type
mice [27]. Interestingly, mice overexpressing PAR1 on cardiomyocytes were protected from
CVB3-induced myocarditis. These transgenic mice exhibited increased levels of IFNβ
expression and reduced levels of virus and reduced cardiac injury [27]. These observations
are consistent with a role of PAR1 in the innate immune response to viral infection. Our
studies suggest that both thrombin and matrix metalloproteinase 13 activate PAR1 during
CVB3 infection [27].
Conclusions
We and others have shown that PAR1 and PAR2 affect to the host response to viral
infection by modulating TLR3 signaling. Further studies are needed to analyze the role of
PARs in different virus infections. There are many open questions about the role of PARs
during virus infections. What is the primary activator of PAR2 in CVB3 infection? A
possible source for a PAR2 activator could be mast cells. Another question is how do PAR1
modulate TLR signaling and the innate immune response in different cell types. We are
currently analyzing the effect of cell type-specific deletion of PAR1 in cardiac fibroblasts or
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cardiomyocytes on CVB3-induced myocarditis to identify the primary site of protective
PAR1 signaling. Another important question is how do PARs modulate TLR signaling. The
most likely possibility is by altering different intracellular signaling pathways. Another
question is do PARs modulate other PRRs? Clearly there is much work to be done in this
field.
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Figure 1. Mackman and Antoniak TR
Effect of PAR1 and PAR2 activation on TLR3-dependent IFNβ expression. CVB3 infection
of cells leads to the generation of dsRNA stimulates TLR3 resulting in IFNβ expression as
part of the antiviral response. The dsRNA mimetic poly I:C can be used to stimulate TLR3.
In cardiac fibroblasts activation of PAR-1 enhances whereas activation of PAR-2 suppresses
TLR3 induction of IFN-β expression.
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